Foghorn Therapeutics (FHTX) Free Cash Flow (2019 - 2026)

Foghorn Therapeutics' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$25.3 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 5.29% year-over-year to -$25.3 million; the TTM figure through Mar 2026 stood at -$87.4 million (up 8.86% YoY), while the FY2025 annual figure was -$86.1 million, up 15.02% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$25.3 million, down from -$22.3 million in the prior quarter.
• The five-year high for Free Cash Flow was $271.3 million in Q1 2022, with the low at -$32.0 million in Q2 2023.
• The 5-year median for Free Cash Flow is -$25.3 million (2026), against an average of -$8.2 million.
• Peak annual rise in Free Cash Flow reached 1225.39% in 2022, while the deepest fall reached 294.87% in 2022.
• Foghorn Therapeutics' Free Cash Flow stood at -$28.9 million in 2022, then climbed by 0.6% to -$28.7 million in 2023, then advanced by 12.92% to -$25.0 million in 2024, then increased by 10.91% to -$22.3 million in 2025, then slipped by 13.45% to -$25.3 million in 2026.
• Business Quant data shows FHTX's Free Cash Flow at -$25.3 million in Q1 2026, -$22.3 million in Q4 2025, and -$18.9 million in Q3 2025.